TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: AUC and Cmax of the betamethasone and OBE001 combination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tmax median delay for OBE001
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of low dietary zinc intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: urinary extravasation
Endpoint domain: Adverse events/effects
Primary endpoint: analgesia requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: AUC0-inf of clopidogrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cm of clopidogrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 of clopidogrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to placement of surgical cricothyrotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Success rate of airway control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: placebo-induced reductions in perceived pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of PTSD symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Severe leg-wound healing disorders
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of knowledge and attitudes towards treating patients with AIDS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Progression of ovarian cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mortality due to progressive disease
Endpoint domain: Mortality/survival
Primary endpoint: T1 relaxation times for menisci
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delay of EIB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean on-treatment costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Combined clinical outcome measure of cardiac death, myocardial infarction and target lesion revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Need for target lesion revascularization
Endpoint domain: Adverse events/effects
Primary endpoint: degree of goal attainment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: societal participation
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: mean number of PEs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to first PE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved survival at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Improved survival at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: Decreased probability of no recurrence at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: recurrent myocardial infarction (reMI) rate
Endpoint domain: Mortality/survival
Primary endpoint: composite rate of death or recurrent myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of hospital-acquired infections
Endpoint domain: Adverse events/effects
Primary endpoint: Collaborative care model effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Chemosensory effects on the upper respiratory tract or eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Star excursion balance test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interest and enjoyment scores from the Intrinsic Motivation Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 3-year primary patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: 3-year secondary patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: limb salvage rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Lag phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of EPA-derived oxylipins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of DHA-derived oxylipins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of arachidonic acid-derived oxylipins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: child total HRQoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Neurological health of newborns at 24-hour examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adaptive capacity scores at half-hour and two-hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: INR of 2.0 or higher
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ALT of 80 IU/L or higher
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: sensitivity of infusion site failure detection algorithm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: false positives per day
Endpoint domain: Adverse events/effects
Primary endpoint: Atrial effective refractory periods (ERPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Atrial conduction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Unintentional pancreatic duct cannulation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: AMS recovery at 90 days postinjury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: refill adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: locoregional recurrence-free survival (LRRFS)
Endpoint domain: Mortality/survival
Primary endpoint: Pain intensity on active standardized movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Objective and subjective knowledge enhancement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Anxiety after consultation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incidence of sleep disturbances
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: increased point abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: less relapse among recent quitters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the time versus concentration curve (AUC) of plasma fexofenadine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration (C(max)) of fexofenadine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fracture incidence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Eradication of gonococcal infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: level of physical activity (total metabolic rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fatigue syndrome
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: plasma nitrate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma nitrite concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: resting systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: brachial blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: central increment index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: major hemorrhagic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity measured by enzyme-linked immunosorbant assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hyperinsulinemic responses to glucose challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CPT score difference between LCIT and placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of NAFLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in mean scores on the IRLS scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with symptoms very much improved or much improved
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of augmentation
Endpoint domain: Adverse events/effects
Primary endpoint: individual time in therapeutic range (i-TTR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall flight performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum NfL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HIV-RNA reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean anterior prosthetic dimension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of posterior adjustments required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevention of ocular itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First-shock ventricular defibrillation efficacy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of systemic inflammatory response syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Number of follicles > 15 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of oocytes recovered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Average number of immature oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion of excellent, good, and satisfactory outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventricle volume decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normal sexual functioning up to 24 h postdosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Overall sex life satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of local and systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity of vaccine components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: disappearance rate of functional ovarian cysts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Overall continence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress-specific continence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-hospital death or transplant
Endpoint domain: Mortality/survival
Primary endpoint: Pack appeal
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative umbilical pain with a need for analgesics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of signs of inflammation of the umbilical wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dehiscence of the umbilical skin sutures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Presence of incisional umbilical hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cardiorespiratory fitness levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnostic score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: knee extensor muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: knee flexor muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: WOMAC score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mental health quality of life improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: improvement in depression score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in grip-lift task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Aortic valve-related events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiovascular death within the first 24 months
Endpoint domain: Mortality/survival
Primary endpoint: Odds of ADE caused by admission prescribing change
Endpoint domain: Adverse events/effects
Primary endpoint: Odds of ADE caused by admission prescribing error
Endpoint domain: Adverse events/effects
Primary endpoint: Admission medication changes documented
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: revision rate
Endpoint domain: Mortality/survival
Primary endpoint: Isokinetic calf muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Ankle performance scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: rTNSS change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of Gleason 7-10 cancer
Endpoint domain: Mortality/survival
Primary endpoint: Child behavior outcomes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: N100 amplitude to auditory stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: AUC of CsA absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of CsA absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tmax of CsA absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risky Behavior Index (RBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risky Substance Use (RSU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to GI-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Concentration of plasma protein carbonylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum scalp temperature variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comprehension difficulties
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Implementation of changes in office operations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Performance of preventive activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hay fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of peripherally-inserted central catheter-related venous thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Use of immunosuppressives
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Increase in bifidobacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Decrease in faecal pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Increase in concentrations of propionic and butyric acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Composite of major CVD events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: median times to eye opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: median times to obeying commands
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: median times to orientation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma fasting glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC((0-24),ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of emesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: CSF leakage rates
Endpoint domain: Adverse events/effects
Primary endpoint: Conjunctival bacterial load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: proportion of women with estimated blood loss >500 mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: percentage of women needing additional uterotonic agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Concentration of propofol in exhaled gas (c(P)G)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of propofol in plasma (c(P)PL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall complication rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: PD-related complication rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: breath hydrogen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Quit all tobacco at 7.5 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-major bleeding incidence
Endpoint domain: Adverse events/effects
Primary endpoint: GERD-related quality of life improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement of GERD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to infinity (AUC∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to reach C max (t max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: general osteoporosis knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: calcium knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ability to implement and maintain healthy behaviors
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Degree of impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 180-day mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Residents' knowledge scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residents' attitudes toward session content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived engagement with session content
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Identification of viable myocardium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dermatologist global assessment score for tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Adherence to treatment protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: V.O(2max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 200 m running performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from any complication
Endpoint domain: Adverse events/effects
Primary endpoint: Withdrawal syndrome relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: depression symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in clinician-rated social anxiety symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants no longer meeting DSM-IV criteria for GSAD
Endpoint domain: Mortality/survival
Primary endpoint: Bioavailability of moxifloxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak concentrations of moxifloxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes